August Troendle Sells 3,510 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 3,510 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total transaction of $2,106,035.10. Following the completion of the sale, the chief executive officer directly owned 638,946 shares in the company, valued at approximately $383,373,989.46. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Medpace Stock Performance

Medpace stock opened at $578.30 on Friday. The stock has a 50-day simple moving average of $504.72 and a 200 day simple moving average of $493.19. The stock has a market capitalization of $16.14 billion, a P/E ratio of 33.90, a PEG ratio of 2.61 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the company earned $3.10 earnings per share. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analyst Ratings Changes

MEDP has been the topic of a number of research analyst reports. BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. TD Cowen increased their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $584.18.

Hedge Funds Weigh In On Medpace

Large investors have recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace in the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new position in Medpace during the 4th quarter worth $30,000. Allied Private Wealth LLC acquired a new stake in shares of Medpace during the second quarter worth $31,000. Basecamp Wealth Advisors LLC lifted its holdings in shares of Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Medpace in the third quarter valued at about $35,000. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.